Janet Hopkins
Chief Tech/Sci/R&D Officer at AURA BIOSCIENCES, INC.
Net worth: 1 M $ as of 2024-04-29
Janet Hopkins active positions
Companies | Position | Start | End |
---|---|---|---|
GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 2022-02-16 | - |
AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-10-15 | - |
Career history of Janet Hopkins
Former positions of Janet Hopkins
Companies | Position | Start | End |
---|---|---|---|
NOVARTIS AG | Corporate Officer/Principal | 2021-10-31 | 2023-09-30 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Chief Executive Officer | 2021-11-30 | 2023-09-30 |
Training of Janet Hopkins
McMaster University | Doctorate Degree |
Statistics
International
United Kingdom | 3 |
United States | 2 |
Switzerland | 2 |
Operational
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
NOVARTIS AG | Health Technology |
Private companies | 2 |
---|---|
Gyroscope Therapeutics Holdings Plc
Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Janet Hopkins
- Experience